All Stories

  1. Impact of rituximab maintenance on survival in patients with mantle cell lymphoma: a population-based cohort study

    Article • Blood Advances, May 2026, American Society of Hematology

    Arjan Diepstra

  2. Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial

    Article • The Lancet Haematology, May 2026, Elsevier

    Arjan Diepstra

  3. Relevance of Epstein-Barr Virus (EBV) miRNAs in EBV-Infected B Cells and B-Cell Lymphomas

    Article • Cancers, March 2026, MDPI AG

    Arjan Diepstra

  4. Author Correction: Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study

    Article • Nature Communications, February 2026, Springer Science + Business Media

    Arjan Diepstra

  5. Non-Invasive Detection of Acute Kidney Allograft Rejection Using [18F]FB-IL2 PET-CT: A First in Human Proof-of-Concept Study

    Article • February 2026, Springer Science + Business Media

    Arjan Diepstra

  6. Intra-erythrocyte creatine, plasma creatine and long-term outcomes in stable kidney transplant recipients: Results from the TransplantLines Biobank and Cohort study

    Article • Clinical Nutrition Open Science, February 2026, Elsevier

    Mrs Coby J.H. Annema, Arjan Diepstra

  7. Symptom Burden and Patient-Reported Outcomes in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Studies

    Article • Kidney Medicine, January 2026, Elsevier

    Mrs Coby J.H. Annema, Arjan Diepstra

  8. Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B‐cell lymphoma patients

    Article • British Journal of Haematology, December 2025, Wiley

    Arjan Diepstra

  9. Overlapping macrophage immune profiles in polymyalgia rheumatica and giant cell arteritis

    Article • Rheumatology, November 2025, Oxford University Press (OUP)

    Arjan Diepstra

  10. Whole-body CD8+ T-cell PET imaging in patients with large B-cell lymphoma before and during CD19-directed CAR T-cell therapy: a phase 2 study

    Article • Nature Communications, November 2025, Springer Science + Business Media

    Arjan Diepstra

  11. Posttransplant Dynamics of Serum T50 and Coronary Artery Calcium Scores Among Kidney Transplant Recipients

    Article • Kidney International Reports, November 2025, Elsevier

    Arjan Diepstra

  12. Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes

    Article • Nature Communications, October 2025, Springer Science + Business Media

    Arjan Diepstra

  13. Plasma creatine, estimated intramuscular creatine and risk of mortality in stable kidney transplant recipients: Results from the TransplantLines biobank and cohort study

    Article • Clinical Nutrition ESPEN, October 2025, Elsevier

    Mrs Coby J.H. Annema, Arjan Diepstra

  14. Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma

    Article • European Journal of Cancer, October 2025, Elsevier

    Arjan Diepstra

  15. Urinary endotrophin as a biomarker for T cell–mediated rejection-associated fibrogenesis in kidney transplant recipients

    Article • Clinical Kidney Journal, September 2025, Oxford University Press (OUP)

    Mrs Coby J.H. Annema, Arjan Diepstra

  16. Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma

    Article • Blood Advances, September 2025, American Society of Hematology

    Arjan Diepstra

  17. Programmed cell death‐1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma

    Article • British Journal of Haematology, August 2025, Wiley

    Arjan Diepstra

  18. Multi-Cohort High-Dimensional Proteomics Reveals Early Risk Markers for Lymphoid Cancer Subtypes

    Article • August 2025, Springer Science + Business Media

    Arjan Diepstra

  19. Serum TARC dynamics during anti‐PD1‐based first‐line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial

    Article • HemaSphere, August 2025, Wiley

    Arjan Diepstra

  20. Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP

    Article • Blood Advances, July 2025, American Society of Hematology

    Arjan Diepstra

  21. IgM Immunohistochemical Expression is a Potential Risk Factor for Extracutaneous Dissemination in Patients With Primary Cutaneous Follicle Center Lymphoma

    Article • The American Journal of Surgical Pathology, June 2025, Wolters Kluwer Health

    Arjan Diepstra

  22. MATRix and HD-MTX/IFO/DEP treatment and autologous stem cell transplantation in secondary central nervous system lymphoma: a Dutch retrospective analysis

    Article • Haematologica, May 2025, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  23. GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica

    Article • Annals of the Rheumatic Diseases, May 2025, Elsevier

    Arjan Diepstra

  24. Superior survival in diffuse large B cell lymphoma of the bone with immune rich tumor microenvironment

    Article • Blood Cancer Journal, April 2025, Springer Science + Business Media

    Arjan Diepstra

  25. Insights in Cellular and Molecular Signatures of the Small Intestinal Graft Posttransplantation: Successful, Recovered, and Rejected—A Case Series

    Article • Transplantation, April 2025, Wolters Kluwer Health

    Mrs Coby J.H. Annema, Arjan Diepstra

  26. Plasma trimethylamine N-oxide concentration and all-cause mortality in kidney transplant recipients

    Article • Nephrology Dialysis Transplantation, April 2025, Oxford University Press (OUP)

    Arjan Diepstra

  27. Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics

    Article • Annals of Hematology, March 2025, Springer Science + Business Media

    Arjan Diepstra

  28. Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma

    Article • Nature Communications, January 2025, Springer Science + Business Media

    Arjan Diepstra

  29. Muscle Mass, Muscle Strength, and Health-Related Quality of Life in Kidney Transplant Recipients

    Article • Kidney International Reports, January 2025, Elsevier

    Mrs Coby J.H. Annema, Arjan Diepstra

  30. Validity of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) tool in a Dutch cohort of transplant recipients

    Article • JEADV Clinical Practice, December 2024, Wiley

    Mrs Coby J.H. Annema, Arjan Diepstra

  31. Clinical characteristics and survival outcomes of patients with primary central nervous system lymphoma treated with high-dose methotrexate-based polychemotherapy and consolidation therapies

    Article • European Journal of Cancer, December 2024, Elsevier

    Arjan Diepstra

  32. Standardization through education of molecular pathology: a spotlight on the European Masters in Molecular Pathology

    Article • Virchows Archiv, October 2024, Springer Science + Business Media

    Arjan Diepstra

  33. The immune pathology of bursitis in rheumatic inflammatory diseases, degenerative conditions and mechanical stress: A systematic review

    Article • Seminars in Arthritis and Rheumatism, October 2024, Elsevier

    Arjan Diepstra

  34. ELISA-4-amyloid: diagnostic accuracy of an ELISA panel for typing the four main types of systemic amyloidosis in subcutaneous abdominal fat tissue samples

    Article • Amyloid, August 2024, Taylor & Francis

    Arjan Diepstra

  35. Calciprotein particle counts associate with vascular remodelling in chronic kidney disease

    Article • Cardiovascular Research, August 2024, Oxford University Press (OUP)

    Arjan Diepstra

  36. Iron deficiency, anemia, and patient-reported outcomes in kidney transplant recipients

    Article • Arabian archaeology and epigraphy, August 2024, Elsevier

    Mrs Coby J.H. Annema, Dion Groothof, Arjan Diepstra

  37. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry

    Article • Blood Advances, July 2024, American Society of Hematology

    Arjan Diepstra

  38. Core regions in immunoglobulin heavy chain enhancers essential for survival of non-Hodgkin lymphoma cells are identified by a CRISPR interference screen

    Article • Haematologica, June 2024, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  39. Plasma symmetric dimethylarginine and kidney graft function in kidney transplant recipients

    Article • Nephrology Dialysis Transplantation, May 2024, Oxford University Press (OUP)

    Mrs Coby J.H. Annema, Dion Groothof, Arjan Diepstra

  40. Memory B-cell derived donor-specific antibodies do not predict outcome in sensitized kidney transplant recipients: a retrospective single-center study

    Article • Frontiers in Immunology, April 2024, Frontiers

    Arjan Diepstra

  41. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR

    Article • BMC Cancer, April 2024, Springer Science + Business Media

    Arjan Diepstra

  42. Pinpointing Functionally Relevant miRNAs in Classical Hodgkin Lymphoma Pathogenesis

    Article • Cancers, March 2024, MDPI AG

    Arjan Diepstra

  43. Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms

    Article • Histopathology, January 2024, Wiley

    Professor Pancras C.W. Hogendoorn, Arjan Diepstra

  44. TOX as a new diagnostic marker for T cell large granular lymphocytic leukaemia

    Article • Histopathology, December 2023, Wiley

    Arjan Diepstra

  45. Health-related quality of life is linked to the gut microbiome in kidney transplant recipients

    Article • Nature Communications, December 2023, Springer Science + Business Media

    Mrs Coby J.H. Annema, Arjan Diepstra

  46. Elevated serum TARC levels precede classic Hodgkin lymphoma diagnosis by several years

    Article • Blood, November 2023, American Society of Hematology

    Arjan Diepstra

  47. R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study

    Article • American Journal of Hematology, November 2023, Wiley

    Arjan Diepstra

  48. Inhibition of the glutamate-cysteine ligase catalytic subunit with buthionine sulfoximine enhances the cytotoxic effect of doxorubicin and cyclophosphamide in Burkitt lymphoma cells

    Article • Journal of Applied Genetics, November 2023, Springer Science + Business Media

    Arjan Diepstra

  49. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy

    Article • Blood Advances, November 2023, American Society of Hematology

    Arjan Diepstra

  50. The Impact of Genetic Subtypes of Diffuse Large B-Cell Lymphoma for Outcome Prediction and Interpretation of FDG-PET treatment Response Monitoring

    Article • October 2023, Springer Science + Business Media

    Arjan Diepstra

  51. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas

    Article • Virchows Archiv, October 2023, Springer Science + Business Media

    Arjan Diepstra

  52. A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma

    Article • Blood Advances, September 2023, American Society of Hematology

    Arjan Diepstra

  53. Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA

    Article • Journal of Hematology & Oncology, September 2023, Springer Science + Business Media

    Arjan Diepstra

  54. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

    Article • Leukemia, September 2023, Springer Science + Business Media

    Arjan Diepstra

  55. A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

    Article • Blood Cancer Journal, September 2023, Springer Science + Business Media

    Arjan Diepstra

  56. Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controls

    Article • Rheumatology, August 2023, Oxford University Press (OUP)

    Arjan Diepstra

  57. Proton Pump Inhibitor Use, Fatigue, and Health-Related Quality of Life in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Study

    Article • American Journal of Kidney Diseases, August 2023, Elsevier

    Mrs Coby J.H. Annema, Arjan Diepstra

  58. Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort study

    Article • EClinicalMedicine, August 2023, Elsevier

    Arjan Diepstra

  59. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748

    Article • Leukemia, July 2023, Springer Science + Business Media

    Arjan Diepstra

  60. Heparin-resistance in AL amyloidosis: a case report

    Article • BMC Anesthesiology, June 2023, Springer Science + Business Media

    Arjan Diepstra

  61. Long non‐coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B‐cell lymphoma

    Article • British Journal of Haematology, May 2023, Wiley

    Arjan Diepstra

  62. M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism

    Article • Science Advances, April 2023, American Association for the Advancement of Science

    Arjan Diepstra

  63. Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica

    Article • Annals of the Rheumatic Diseases, March 2023, Elsevier

    Arjan Diepstra

  64. The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics

    Article • Histopathology, November 2022, Wiley

    Arjan Diepstra

  65. Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma

    Article • International Journal of Molecular Sciences, November 2022, MDPI AG

    Arjan Diepstra

  66. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis

    Article • European Journal of Cancer, November 2022, Elsevier

    Arjan Diepstra

  67. Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

    Article • Leukemia, October 2022, Springer Science + Business Media

    Arjan Diepstra

  68. Classification of Amyloidosis SubTypes by Synchrotron InfraRed MicroSpectroscopy

    Article • October 2022, Research Square

    Arjan Diepstra

  69. T027: High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years

    Article • HemaSphere, October 2022, Wiley

    Arjan Diepstra

  70. Hand dexterity, daily functioning and health-related quality of life in kidney transplant recipients

    Article • Scientific Reports, September 2022, Springer Science + Business Media

    Mrs Coby J.H. Annema, Arjan Diepstra

  71. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica

    Article • Frontiers in Immunology, August 2022, Frontiers

    Arjan Diepstra

  72. The lncRNA KTN1-AS1 co-regulates a variety of Myc-target genes and enhances proliferation of Burkitt lymphoma cells

    Article • Human Molecular Genetics, July 2022, Oxford University Press (OUP)

    Arjan Diepstra

  73. Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals

    Article • Blood Advances, July 2022, American Society of Hematology

    Arjan Diepstra

  74. Renal Endothelial Cytotoxicity Assay to Diagnose and Monitor Renal Transplant Recipients for Anti-Endothelial Antibodies

    Article • Frontiers in Immunology, June 2022, Frontiers

    Arjan Diepstra

  75. Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer

    Article • Cancers, May 2022, MDPI AG

    Arjan Diepstra

  76. Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney

    Article • Frontiers in Immunology, April 2022, Frontiers

    Arjan Diepstra

  77. Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach

    Article • Cancers, April 2022, MDPI AG

    Arjan Diepstra

  78. Reproducibility of Gene Expression Signatures in Diffuse Large B-Cell Lymphoma

    Article • Cancers, March 2022, MDPI AG

    Arjan Diepstra

  79. Low Mutational Burden of Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome

    Article • Cancers, February 2022, MDPI AG

    Arjan Diepstra

  80. A gene expression–based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma

    Article • Blood, February 2022, American Society of Hematology

    Arjan Diepstra

  81. CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2

    Article • OncoImmunology, January 2022, Taylor & Francis

    Arjan Diepstra

  82. Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma

    Article • Frontiers in Immunology, January 2022, Frontiers

    Arjan Diepstra

  83. Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas

    Article • Virchows Archiv, January 2022, Springer Science + Business Media

    Arjan Diepstra

  84. Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing

    Article • Leukemia & Lymphoma, December 2021, Taylor & Francis

    Arjan Diepstra

  85. Plasma Lead Concentration and Risk of Late Kidney Allograft Failure: Findings From the TransplantLines Biobank and Cohort Studies

    Article • American Journal of Kidney Diseases, December 2021, Elsevier

    Dr Camilo G. Sotomayor, Dion Groothof, Mrs Coby J.H. Annema, Arjan Diepstra

  86. HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients

    Article • Cancers, November 2021, MDPI AG

    Professor Ruth Frances Jarrett, Arjan Diepstra

  87. Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment

    Article • Annals of Hematology, November 2021, Springer Science + Business Media

    Arjan Diepstra

  88. Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren's Syndrome

    Article • Blood, November 2021, American Society of Hematology

    Arjan Diepstra

  89. Boron Intake and decreased risk of mortality in kidney transplant recipients

    Article • European Journal of Nutrition, October 2021, Springer Science + Business Media

    Dion Groothof, Arjan Diepstra

  90. Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL)

    Article • Cancers, October 2021, MDPI AG

    Arjan Diepstra

  91. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

    Article • Leukemia, September 2021, Springer Science + Business Media

    Arjan Diepstra

  92. Aggravation of fibrin deposition and microthrombus formation within the graft during kidney transplantation

    Article • Scientific Reports, September 2021, Springer Science + Business Media

    Arjan Diepstra

  93. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial

    Article • British Journal of Haematology, September 2021, Wiley

    Arjan Diepstra

  94. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

    Article • Blood Advances, September 2021, American Society of Hematology

    Professor Pancras C.W. Hogendoorn, Arjan Diepstra

  95. Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality

    Article • Blood Advances, August 2021, American Society of Hematology

    Arjan Diepstra

  96. A Rare Case of Epstein-Barr Virus–Positive T-Cell Lymphoma in the Skin of an Immunocompromised Patient

    Article • American Journal of Dermatopathology, August 2021, Wolters Kluwer Health

    Arjan Diepstra

  97. Case report of a clinically indolent but morphologically high‐grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?

    Article • Journal of Cutaneous Pathology, July 2021, Wiley

    Arjan Diepstra

  98. Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing

    Article • Nature Communications, June 2021, Springer Science + Business Media

    Arjan Diepstra

  99. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy

    Article • European Journal of Pediatrics, June 2021, Springer Science + Business Media

    Arjan Diepstra

  100. Non‐small‐cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy

    Article • Histopathology, April 2021, Wiley

    Arjan Diepstra

  101. Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma

    Article • British Journal of Haematology, February 2021, Wiley

    Arjan Diepstra

  102. Genetically Raised Circulating Bilirubin Levels and Risk of Ten Cancers: A Mendelian Randomization Study

    Article • Cells, February 2021, MDPI AG

    Professor Ruth Frances Jarrett, Arjan Diepstra

  103. Interaction between ERAP Alleles and HLA Class I Types Support a Role of Antigen Presentation in Hodgkin Lymphoma Development

    Article • Cancers, January 2021, MDPI AG

    Arjan Diepstra

  104. Semi-Quantitative Characterization of Post-Transplant Lymphoproliferative Disorder Morphological Subtypes with [18F]FDG PET/CT

    Article • Journal of Clinical Medicine, January 2021, MDPI AG

    Arjan Diepstra

  105. Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: Diagnosis and Treatment

    Article • HemaSphere, January 2021, Wiley

    Arjan Diepstra

  106. Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis

    Article • Blood Advances, December 2020, American Society of Hematology

    Arjan Diepstra

  107. Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58

    Article • Blood, November 2020, American Society of Hematology

    Arjan Diepstra

  108. Biopsy-Controlled Non-Invasive Quantification of Collagen Type VI in Kidney Transplant Recipients: A Post-Hoc Analysis of the MECANO Trial

    Article • Journal of Clinical Medicine, October 2020, MDPI AG

    Dr Camilo G. Sotomayor, Arjan Diepstra

  109. Galectin-3 and Risk of Late Graft Failure in Kidney Transplant Recipients: A 10-year Prospective Cohort Study

    Article • Transplantation, June 2020, Wolters Kluwer Health

    Dr Camilo G. Sotomayor, Arjan Diepstra

  110. Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy

    Article • The Lancet Haematology, June 2020, Elsevier

    Arjan Diepstra

  111. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

    Article • Haematologica, April 2020, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  112. Cell-free DNA as biomarker in Hodgkin lymphoma patients

    Article • Klinische Pädiatrie, March 2020, Thieme Publishing Group

    Arjan Diepstra

  113. Interim thymus and activation regulated chemokine versus interim 18F‐fluorodeoxyglucose positron‐emission tomography in classical Hodgkin lymphoma response evaluation

    Article • British Journal of Haematology, February 2020, Wiley

    Arjan Diepstra

  114. 18F-FDG PET/CT in the Diagnostic and Treatment Evaluation of Pediatric Posttransplant Lymphoproliferative Disorders

    Article • Journal of Nuclear Medicine, January 2020, Society of Nuclear Medicine

    Arjan Diepstra

  115. Microenvironment, Cross-Talk, and Immune Escape Mechanisms

    Article • January 2020, Springer Science + Business Media

    Arjan Diepstra

  116. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma

    Article • Cancer Treatment Reviews, January 2020, Elsevier

    Arjan Diepstra

  117. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial

    Article • Haematologica, December 2019, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  118. Complement activation and long-term graft function in ABO-incompatible kidney transplantation

    Article • World Journal of Nephrology, October 2019, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Arjan Diepstra

  119. CD27+CD38hi B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients

    Article • Frontiers in Immunology, September 2019, Frontiers

    Arjan Diepstra

  120. Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

    Article • European Journal of Pediatrics, August 2019, Springer Science + Business Media

    Arjan Diepstra

  121. Relationship between semiquantitative 18F-fluorodeoxyglucose positron emission tomography metrics and necrosis in classical Hodgkin lymphoma

    Article • Scientific Reports, July 2019, Springer Science + Business Media

    Arjan Diepstra

  122. Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements

    Article • European Radiology, April 2019, Springer Science + Business Media

    Arjan Diepstra

  123. Correction

    Article • American Journal Of Pathology, February 2019, Elsevier

    Arjan Diepstra

  124. Massive B-Cell Infiltration and Organization Into Artery Tertiary Lymphoid Organs in the Aorta of Large Vessel Giant Cell Arteritis

    Article • Frontiers in Immunology, January 2019, Frontiers

    Arjan Diepstra

  125. Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment

    Article • Haematologica, December 2018, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  126. Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma

    Article • Cancers, November 2018, MDPI AG

    Arjan Diepstra

  127. Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones

    Article • Cancer Cell, October 2018, Elsevier

    Arjan Diepstra

  128. Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment

    Article • Haematologica, August 2018, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  129. Interobserver variation in CD30 immunohistochemistry interpretation; consequences for patient selection for targeted treatment

    Article • Histopathology, June 2018, Wiley

    Arjan Diepstra

  130. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma

    Article • Blood, May 2018, American Society of Hematology

    Arjan Diepstra

  131. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation

    Article • Blood, May 2018, American Society of Hematology

    Arjan Diepstra

  132. Argonaute 2 RNA Immunoprecipitation Reveals Distinct miRNA Targetomes of Primary Burkitt Lymphoma Tumors and Normal B Cells

    Article • American Journal Of Pathology, May 2018, Elsevier

    Arjan Diepstra

  133. The Microenvironment in Epstein–Barr Virus-Associated Malignancies

    Article • Pathogens, April 2018, MDPI AG

    Geok Wee Tan, Arjan Diepstra

  134. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform

    Article • Melanoma Research, April 2018, Wolters Kluwer Health

    Arjan Diepstra

  135. Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries

    Article • Annals of the Rheumatic Diseases, March 2018, Elsevier

    Arjan Diepstra

  136. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach

    Article • PLOS One, February 2018, PLOS

    Arjan Diepstra

  137. Combined loss of HLA I and HLA II expression is more common in the non‐GCB type of diffuse large B cell lymphoma

    Article • Histopathology, January 2018, Wiley

    Arjan Diepstra

  138. Erratum: The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor

    Article • Blood Cancer Journal, January 2018, Springer Science + Business Media

    Arjan Diepstra

  139. Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127

    Article • International Journal of Molecular Sciences, January 2018, MDPI AG

    Arjan Diepstra

  140. Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma

    Article • Annals of Hematology, January 2018, Springer Science + Business Media

    Arjan Diepstra

  141. MicroRNA High Throughput Loss-of-Function Screening Reveals an Oncogenic Role for miR-21-5p in Hodgkin Lymphoma

    Article • Cellular Physiology and Biochemistry, January 2018, Karger Publishers

    Arjan Diepstra

  142. MYC Rearrangement Positive Large B-Cell Lymphoma Patients Can Be Treated Successfully with R-CHOP Plus Lenalidomide: Results of a Multicentre Phase II HOVON Trial

    Article • SSRN Electronic Journal, January 2018, Elsevier

    Arjan Diepstra

  143. Emerging roles for long noncoding RNAs in B-cell development and malignancy

    Article • Critical Reviews in Oncology/Hematology, December 2017, Elsevier

    Arjan Diepstra

  144. Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma

    Article • Journal of Clinical Oncology, November 2017, American Society of Clinical Oncology (ASCO)

    Arjan Diepstra

  145. Relapse in stage I(E) diffuse large B-cell lymphoma

    Article • Hematological Oncology, October 2017, Wiley

    Arjan Diepstra

  146. Human alternative Klotho mRNA is a nonsense-mediated mRNA decay target inefficiently spliced in renal disease

    Article • JCI Insight, October 2017, American Society for Clinical Investigation

    Arjan Diepstra

  147. Targeting the Microenvironment in Hodgkin Lymphoma: Opportunities and Challenges

    Article • October 2017, Springer Science + Business Media

    Arjan Diepstra

  148. Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome

    Article • Blood Advances, June 2017, American Society of Hematology

    Arjan Diepstra

  149. High human cytomegalovirus DNAemia early post-transplantation associates with irreversible and progressive loss of renal function - a retrospective study

    Article • Transplant International, June 2017, Wiley

    Professor Hubert G Niesters, Arjan Diepstra

  150. A delicate balance between rejection and BK polyomavirus associated nephropathy; A retrospective cohort study in renal transplant recipients

    Article • PLOS One, June 2017, PLOS

    Arjan Diepstra

  151. miR-24-3p Is Overexpressed in Hodgkin Lymphoma and Protects Hodgkin and Reed-Sternberg Cells from Apoptosis

    Article • American Journal Of Pathology, June 2017, Elsevier

    Arjan Diepstra

  152. Kidney Involvement in Systemic Calcitonin Amyloidosis Associated With Medullary Thyroid Carcinoma

    Article • American Journal of Kidney Diseases, April 2017, Elsevier

    Arjan Diepstra

  153. ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma

    Article • Leukemia, March 2017, Springer Science + Business Media

    Arjan Diepstra

  154. HLA expression and HLA type associations in relation to EBV status in Hispanic Hodgkin lymphoma patients

    Article • PLOS One, March 2017, PLOS

    Arjan Diepstra

  155. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

    Article • OncoImmunology, March 2017, Taylor & Francis

    Arjan Diepstra

  156. Human Cytomegalovirus-Encoded Receptor US28 Is Expressed in Renal Allografts and Facilitates Viral Spreading In Vitro

    Article • Transplantation, March 2017, Wolters Kluwer Health

    Arjan Diepstra

  157. Novel treatment concepts in Hodgkin lymphoma

    Article • Journal of Internal Medicine, December 2016, Wiley

    Arjan Diepstra

  158. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma

    Article • International Journal of Molecular Sciences, December 2016, MDPI AG

    Arjan Diepstra

  159. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin‐1, sCD163 and sCD30 with TARC

    Article • British Journal of Haematology, September 2016, Wiley

    Arjan Diepstra

  160. Progression of a solitary plasmacytoma to multiple myeloma. A population‐based registry of the northern Netherlands

    Article • British Journal of Haematology, September 2016, Wiley

    Arjan Diepstra

  161. Long Noncoding RNA Expression Profiling in Normal B-Cell Subsets and Hodgkin Lymphoma Reveals Hodgkin and Reed-Sternberg Cell–Specific Long Noncoding RNAs

    Article • American Journal Of Pathology, September 2016, Elsevier

    Arjan Diepstra

  162. CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse

    Article • Genes & Immunity, July 2016, Springer Science + Business Media

    Arjan Diepstra

  163. Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia

    Article • British Journal of Haematology, July 2016, Wiley

    Arjan Diepstra

  164. Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity

    Article • Pediatric Nephrology, June 2016, Springer Science + Business Media

    Arjan Diepstra

  165. The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein–Barr virus presence and location within the tumor

    Article • Blood Cancer Journal, May 2016, Springer Science + Business Media

    Arjan Diepstra

  166. Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas

    Article • PLOS One, January 2016, PLOS

    Arjan Diepstra

  167. Mutations in CD58 and Other Immune System Related Genes in Hodgkin Lymphoma

    Article • Blood, December 2015, American Society of Hematology

    Arjan Diepstra

  168. Mir-155 Enhances B-Cell Lymphoma Growth By Targeting TBRG1

    Article • Blood, December 2015, American Society of Hematology

    Arjan Diepstra

  169. Inhibition of the miR-155 target NIAM phenocopies the growth promoting effect of miR-155 in B-cell lymphoma

    Article • Oncotarget, October 2015, Impact Journals, LLC

    Arjan Diepstra

  170. A Novel Risk Locus at 6p21.3 for Epstein-Barr Virus-Positive Hodgkin Lymphoma

    Article • Cancer Epidemiology Biomarkers & Prevention, September 2015, American Association for Cancer Research (AACR)

    Professor Ruth Frances Jarrett, Arjan Diepstra

  171. CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma

    Article • Experimental Hematology and Oncology, September 2015, Springer Science + Business Media

    Arjan Diepstra

  172. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers

    Article • Oncotarget, April 2015, Impact Journals, LLC

    Arjan Diepstra

  173. Paediatric nodal marginal zone B-cell lymphadenopathy of the neck: aHaemophilus influenzae-driven immune disorder?

    Article • The Journal of Pathology, April 2015, Wiley

    Arjan Diepstra

  174. Long noncoding RNAs as a novel component of the Myc transcriptional network

    Article • The FASEB Journal, February 2015, Wiley

    Arjan Diepstra

  175. Microenvironment, Crosstalk, and Immune Escape Mechanisms

    Article • December 2014, Springer Science + Business Media

    Arjan Diepstra

  176. Genetic Associations in Classical Hodgkin Lymphoma: A Systematic Review and Insights into Susceptibility Mechanisms

    Article • Cancer Epidemiology Biomarkers & Prevention, December 2014, American Association for Cancer Research (AACR)

    Arjan Diepstra

  177. Epstein–Barr virus, the germinal centre and the development of Hodgkin’s lymphoma

    Article • Journal of General Virology, September 2014, Society for General Microbiology

    Arjan Diepstra

  178. Toll-like receptors in the pathogenesis of human B cell malignancies

    Article • Journal of Hematology & Oncology, August 2014, Springer Science + Business Media

    Arjan Diepstra

  179. The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing

    Article • Leukemia, June 2014, Springer Science + Business Media

    Arjan Diepstra

  180. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

    Article • Nature Communications, June 2014, Springer Science + Business Media

    Professor Ruth Frances Jarrett, Arjan Diepstra

  181. The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component

    Article • Seminars in Cancer Biology, February 2014, Elsevier

    Arjan Diepstra

  182. Insulin-Like Growth Factor 1 Receptor Is a Prognostic Factor in Classical Hodgkin Lymphoma

    Article • PLOS One, January 2014, PLOS

    Arjan Diepstra

  183. The renal angiopoietin/Tie2 system in lethal human sepsis

    Article • Critical Care, January 2014, Springer Science + Business Media

    Arjan Diepstra

  184. Specific PML Isoforms and SATB1 Affect HLA Expression In Classical Hodgkin Lymphoma

    Article • Blood, November 2013, American Society of Hematology

    Arjan Diepstra

  185. The Role of MicroRNAs in Hodgkin's Lymphoma

    Article • November 2013, Wiley

    Arjan Diepstra

  186. PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV+ Hodgkin Lymphoma

    Article • PLOS One, August 2013, PLOS

    Arjan Diepstra

  187. A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis

    Article • Haematologica, May 2013, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  188. Expression, Prognostic Value and Function of IGF1R in Hodgkin Lymphoma.

    Article • Blood, November 2012, American Society of Hematology

    Arjan Diepstra

  189. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma

    Article • Blood, October 2012, American Society of Hematology

    Arjan Diepstra

  190. HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters

    Article • PLOS One, July 2012, PLOS

    Arjan Diepstra

  191. Huang X, Kushekhar K, Nolte I, Kooistra W, Visser L, Bouwman I, Kouprie N, Veenstra R, van Imhoff G, Olver B, Houlston RS, Poppema S, Diepstra A, Hepkema B, van den Berg A. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV ...

    Article • Blood, April 2012, American Society of Hematology

    Arjan Diepstra

  192. HLA-A*02:07 Is a Protective Allele for EBV Negative and a Susceptibility Allele for EBV Positive Classical Hodgkin Lymphoma in China

    Article • PLOS One, February 2012, PLOS

    Arjan Diepstra

  193. Lithium induces intestinothrophic effects in the healthy colon, but does not ameliorate dextran sulfate sodium-induced colitis in mice

    Article • e-SPEN Journal, February 2012, Elsevier

    Arjan Diepstra

  194. Genome-Wide Association Study of Classical Hodgkin Lymphoma and Epstein–Barr Virus Status–Defined Subgroups

    Article • JNCI Journal of the National Cancer Institute, January 2012, Oxford University Press (OUP)

    Professor Ruth Frances Jarrett, Arjan Diepstra

  195. Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma

    Article • Haematologica, December 2011, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  196. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups

    Article • Blood, November 2011, American Society of Hematology

    Arjan Diepstra

  197. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma

    Article • Haematologica, November 2011, Ferrata Storti Foundation (Haematologica)

    Arjan Diepstra

  198. MiR‐17/106b seed family regulates p21 in Hodgkin's lymphoma

    Article • The Journal of Pathology, September 2011, Wiley

    Arjan Diepstra

  199. Epidemiology of Classical Hodgkin Lymphoma and Its Association with Epstein Barr Virus in Northern China

    Article • PLOS One, June 2011, PLOS

    Arjan Diepstra

  200. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

    Article • Nature, March 2011, Springer Science + Business Media

    Arjan Diepstra

  201. Protective and Predisposing HLA Alleles In Dutch Classical Hodgkin Lymphoma Patients

    Article • Blood, November 2010, American Society of Hematology

    Arjan Diepstra

  202. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

    Article • Nature Genetics, October 2010, Springer Science + Business Media

    Professor Ruth Frances Jarrett, Arjan Diepstra

  203. Microenvironment, Cross-Talk, and Immune Escape Mechanisms

    Article • August 2010, Springer Science + Business Media

    Arjan Diepstra

  204. Expression of CD1d and presence of invariant NKT cells in classical Hodgkin lymphoma

    Article • American Journal of Hematology, June 2010, Wiley

    Arjan Diepstra

  205. Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients

    Article • PLOS One, May 2010, PLOS

    Arjan Diepstra

  206. Endoscopic detection of an early manifestation of EBV-related post-transplant lymphoproliferative disorder in a transplanted colon

    Article • Endoscopy, March 2010, Thieme Publishing Group

    Arjan Diepstra

  207. MHC class II as a therapeutic target in B-cell lymphomas: the CIITA road to paradise?

    Article • Leukemia & Lymphoma, October 2009, Taylor & Francis

    Arjan Diepstra

  208. Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin's Lymphoma Predicts Adverse Outcome in Older Adult Patients

    Article • Journal of Clinical Oncology, August 2009, American Society of Clinical Oncology (ASCO)

    Arjan Diepstra

  209. miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes

    Article • Laboratory Investigation, June 2009, Elsevier

    Arjan Diepstra

  210. Beneath the Surface

    Article • The American Journal of Medicine, February 2009, Elsevier

    Arjan Diepstra

  211. Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

    Article • British Journal of Haematology, March 2008, Wiley

    Professor Ruth Frances Jarrett, Arjan Diepstra

  212. Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes

    Article • Blood, February 2008, American Society of Hematology

    Arjan Diepstra

  213. HLA‐G protein expression as a potential immune escape mechanism in classical Hodgkin’s lymphoma

    Article • Tissue Antigens, February 2008, Wiley

    Arjan Diepstra

  214. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma

    Article • Blood, November 2007, American Society of Hematology

    Professor Ruth Frances Jarrett, Arjan Diepstra

  215. HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma

    Article • Journal of Clinical Oncology, July 2007, American Society of Clinical Oncology (ASCO)

    Arjan Diepstra

  216. The Human Leukocyte Antigen Class I Region Is Associated with EBV-Positive Hodgkin's Lymphoma: HLA-A and HLA Complex Group 9 Are Putative Candidate Genes

    Article • Cancer Epidemiology Biomarkers & Prevention, October 2006, American Association for Cancer Research (AACR)

    Professor Ruth Frances Jarrett, Arjan Diepstra

  217. Global correlation of genome and transcriptome changes in classical Hodgkin lymphoma

    Article • Hematological Oncology, October 2006, Wiley

    Arjan Diepstra

  218. A factorial experiment for optimizing the PCR conditions in routine genotyping

    Article • Biotechnology and Applied Biochemistry, October 2005, Wiley

    Arjan Diepstra

  219. Genetic susceptibility to Hodgkin's lymphoma associated with the human leukocyte antigen region

    Article • European Journal Of Haematology, June 2005, Wiley

    Arjan Diepstra

  220. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma

    Article • The Lancet, June 2005, Elsevier

    Arjan Diepstra

  221. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma

    Article • Journal of Clinical Pathology, April 2005, BMJ

    Arjan Diepstra

  222. Immune Dysfunction in Classical Hodgkin’s Lymphoma

    Article • January 2004, Springer Science + Business Media

    Arjan Diepstra

  223. High expression of B‐cell receptor inducible gene BIC in all subtypes of Hodgkin lymphoma

    Article • Genes Chromosomes and Cancer, March 2003, Wiley

    Arjan Diepstra

  224. Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma

    Article • American Journal Of Pathology, January 2003, Elsevier

    Arjan Diepstra

  225. Clonal relation in a case of CLL, ALCL, and Hodgkin composite lymphoma

    Article • Blood, August 2002, American Society of Hematology

    Arjan Diepstra

  226. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomas

    Article • International Journal of Cancer, May 2002, Wiley

    Arjan Diepstra

  227. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues

    Article • Annals of Oncology, April 2002, Elsevier

    Arjan Diepstra

  228. Germline FAS gene mutation in a case of ALPS and NLP Hodgkin lymphoma

    Article • Blood, February 2002, American Society of Hematology

    Arjan Diepstra

  229. Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy

    Article • Proceedings of the National Academy of Sciences, March 1998, Proceedings of the National Academy of Sciences

    Arjan Diepstra